{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:51:57Z","timestamp":1782417117702,"version":"3.54.5"},"reference-count":58,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100031288","name":"F2G","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.cmi.2024.01.015","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T08:29:57Z","timestamp":1706430597000},"page":"755-761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["How do I manage refractory invasive pulmonary aspergillosis"],"prefix":"10.1016","volume":"30","author":[{"given":"Paschalis","family":"Vergidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parham","family":"Sendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan B.","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.01.015_bib1","first-page":"550","article-title":"The burden of invasive aspergillosis in patients with haematological malignancy: a meta-analysis and systematic review","volume":"76","author":"van de Peppel","year":"2018","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2024.01.015_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12981","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: a Swiss transplant cohort study","volume":"20","author":"Kuster","year":"2018","journal-title":"Transpl Infect Dis"},{"issue":"Suppl.\u00a07","key":"10.1016\/j.cmi.2024.01.015_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.cmi.2024.01.015_bib4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.cmi.2024.01.015_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.01.015_bib7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/cid\/civ507","article-title":"Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing","volume":"61","author":"White","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.01.015_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2024.01.015_bib12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2024.01.015_bib13","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/ctr.12834","article-title":"Adverse effects of voriconazole: over a decade\u00a0of\u00a0use","volume":"30","author":"Levine","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cmi.2024.01.015_bib14","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study","volume":"45","author":"Herbrecht","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.01.015_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1471-2334-10-182","article-title":"Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry","volume":"10","author":"Maertens","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib17","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection-position paper of the mycoses study group education and research consortium and the European confederation of medical mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2024.01.015_bib18","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.cmi.2021.02.021","article-title":"Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study","volume":"27","author":"Danion","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.01.015_bib19","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cmi.2018.11.027","article-title":"Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management","volume":"25","author":"Lestrade","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.01.015_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2024.01.015_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00548-19","article-title":"Elevated prevalence of azole-resistant Aspergillus fumigatus in urban versus rural environments in the United Kingdom","volume":"63","author":"Sewell","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00392-19","article-title":"Nonrandom distribution of azole resistance across the global population of Aspergillus fumigatus","volume":"10","author":"Sewell","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2024.01.015_bib23","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/JCM.00854-09","article-title":"Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network","volume":"47","author":"Baddley","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2024.01.015_bib24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib25","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib26","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study","volume":"68","author":"Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib27","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciaa230","article-title":"Invasive aspergillosis due to Aspergillus section Usti: a multicenter retrospective study","volume":"72","author":"Glampedakis","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib28","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1128\/JCM.05946-11","article-title":"Cross-reactivity of Fusarium spp. in the Aspergillus galactomannan enzyme-linked immunosorbent assay","volume":"50","author":"Tortorano","year":"2012","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2024.01.015_bib29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QCO.0000000000000662","article-title":"Aspergillus fumigatus and pan-azole resistance: who should be concerned?","volume":"33","author":"Wiederhold","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2024.01.015_bib32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijid.2014.07.007","article-title":"Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis","volume":"28","author":"Panackal","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib33","doi-asserted-by":"crossref","DOI":"10.21767\/2471-8521.100012","article-title":"Combination antifungal therapy for invasive aspergillosis revisited","volume":"2","author":"Panackal","year":"2016","journal-title":"Med Mycol Open Access"},{"key":"10.1016\/j.cmi.2024.01.015_bib34","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2024.01.015_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01527-20","article-title":"Olorofim susceptibility testing of 1,423 Danish mold isolates obtained in 2018-2019 confirms uniform and broad-spectrum activity","volume":"65","author":"Astvad","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.05.013","article-title":"In\u00a0vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and\/or amphotericin B","volume":"28","author":"Escribano","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.01.015_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00849-22","article-title":"EUCAST-Obtained Olorofim MICs against Aspergillus and Scedosporium species and Lomentospora prolificans showed high agreements between visual inspection and spectrophotometric readings","volume":"66","author":"Escribano","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib38","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1093\/jac\/dkaa351","article-title":"In\u00a0vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies","volume":"75","author":"Rivero-Menendez","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib39","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/jac\/dkaa562","article-title":"In\u00a0vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species","volume":"76","author":"Singh","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib40","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01623-22","article-title":"Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers","volume":"67","author":"Hodges","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02368-21","article-title":"Case commentary: long-term fosmanogepix use in a transplant recipient with disseminated aspergillosis caused by azole-resistant Aspergillus calidoustus","volume":"66","author":"Kline","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00380-22","article-title":"The combination treatment of fosmanogepix and liposomal amphotericin b is superior to monotherapy in treating experimental invasive mold infections","volume":"66","author":"Gebremariam","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01735-19","article-title":"Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis","volume":"64","author":"Alkhazraji","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02343-20","article-title":"Manogepix, the active moiety of the investigational agent fosmanogepix, demonstrates in\u00a0vitro activity against members of the fusarium oxysporum and fusarium solani species complexes","volume":"65","author":"Badali","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00178-20","article-title":"Fosmanogepix (APX001) Is Effective in the treatment of pulmonary murine mucormycosis due to rhizopus arrhizus","volume":"64","author":"Gebremariam","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01966-19","article-title":"Galactomannan is a biomarker of fosmanogepix (APX001) efficacy in treating experimental invasive pulmonary aspergillosis","volume":"64","author":"Gebremariam","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02476-20","article-title":"Therapeutic potential of fosmanogepix (APX001) for intra-abdominal candidiasis: from lesion penetration to efficacy in a mouse model","volume":"65","author":"Lee","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib49","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1128\/AAC.00432-11","article-title":"Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors","volume":"55","author":"Walker","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib50","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in\u00a0vivo murine invasive candidiasis model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib51","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in\u00a0vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates","volume":"58","author":"Jim\u00e9nez-Ortigosa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib52","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","article-title":"In\u00a0vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods","volume":"57","author":"Pfaller","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.01.015_bib53","article-title":"In\u00a0vitro activity of ibrexafungerp against a collection of clinical isolates of aspergillus, including cryptic species and Cyp51A mutants, using EUCAST and CLSI methodologies","volume":"7","author":"Rivero-Menendez","year":"2021","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.cmi.2024.01.015_bib54","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/cid\/ciab750","article-title":"Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)","volume":"74","author":"Schwebke","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib55","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/cid\/ciad002","article-title":"New Antifungals for vulvovaginal candidiasis: what is their role?","volume":"76","author":"Sobel","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.01.015_bib56","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1471-0528.16972","article-title":"Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306)","volume":"129","author":"Sobel","year":"2022","journal-title":"Bjog"},{"key":"10.1016\/j.cmi.2024.01.015_bib57","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40265-021-01571-5","article-title":"Ibrexafungerp: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2024.01.015_bib58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:10:24Z","timestamp":1762366224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1198743X24000375"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.01.015","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How do I manage refractory invasive pulmonary aspergillosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}